keyword
MENU ▼
Read by QxMD icon Read
search

Kras g12c

keyword
https://www.readbyqxmd.com/read/27870730/cutaneous-sebaceous-lesions-in-a-patient-with-mutyh-associated-polyposis-mimicking-muir-torre-syndrome
#1
Denisa Kacerovska, Lubomir Drlik, Lenka Slezakova, Michal Michal, Jan Stehlik, Monika Sedivcova, Ladislav Hadravsky, Dmitry V Kazakov
A 76-year-old white male with a history of adenocarcinoma of the rectosigmoideum and multiple colonic polyps removed at the age of 38 and 39 years by an abdominoperitoneal amputation and total colectomy, respectively, presented with multiple whitish and yellowish papules on the face and a verrucous lesion on the trunk. The lesions were surgically removed during the next 3 years and a total of 13 lesions were investigated histologically. The diagnoses included 11 sebaceous adenomas, 1 low-grade sebaceous carcinoma, and 1 squamous cell carcinoma...
December 2016: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/27728979/rationale-for-ras-mutation-tailored-therapies
#2
Steven K Montalvo, Lianbo Li, Kenneth D Westover
RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies...
October 12, 2016: Future Oncology
https://www.readbyqxmd.com/read/27637917/somatic-mutation-analysis-of-kras-braf-her2-and-pten-in-egfr-mutation-negative-non-small-cell-lung-carcinoma-determination-of-frequency-distribution-pattern-and-identification-of-novel-deletion-in-her2-gene-from-indian-patients
#3
Sangeet Bhaumik, Firoz Ahmad, Bibhu Ranjan Das
Somatic mutations of KRAS, BRAF, HER2, PTEN genes are the most important molecular markers after the EGFR gene mutation. The current study evaluated the frequency and distribution pattern of KRAS, BRAF, HER2, PTEN mutation in Indian non-small cell lung carcinoma patients. The frequency of KRAS, BRAF, HER2, PTEN mutations was 6.4 % (14/204), 1.5 % (3/204), 1.5 % (3/204), 0 % (0/204), respectively. KRAS, BRAF, HER2 mutations were more prevalent in males than in females. KRAS and HER2 showed a trend of a higher frequency of mutation in the age group of <60 years, whereas BRAF mutations were more frequent in the age group of ≥60 years...
October 2016: Medical Oncology
https://www.readbyqxmd.com/read/27632281/optimized-multiplex-detection-of-7-kras-mutations-by-taqman-allele-specific-qpcr
#4
Andrea Orue, Manuel Rieber
UNLABELLED: Establishing the KRAS mutational status of tumor samples is essential to manage patients with colorectal or lung cancer, since these mutations preclude treatment with monoclonal anti-epidermal growth factor receptor (EGFR) antibodies. We report an inexpensive, rapid multiplex allele-specific qPCR method detecting the 7 most clinically relevant KRAS somatic mutations with concomitant amplification of non-mutated KRAS in tumor cells and tissues from CRC patients. Positive samples evidenced in the multiplex assay were further subjected to individual allele-specific analysis, to define the specific mutation...
2016: PloS One
https://www.readbyqxmd.com/read/27597976/necessity-of-microdissecting-different-tumor-components-in-pulmonary-tumor-pyrosequencing
#5
Dahui Qin, Zhong Zheng, Shanxiang Shen, Prudence Smith, Farah K Khalil
Microdissection is a useful method in tissue sampling prior to molecular testing. Tumor heterogeneity imposes new challenges for tissue sampling. Different microdissecting methods have been employed in face of such challenge. We improved our microdissection method by separately microdissecting the morphologically different tumor components. This improvement helped the pyrosequencing data analysis of two specimens. One specimen consisted of both adenocarcinoma and neuroendocrine components. When both tumor components were sequenced together for KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutations, the resulting pyrogram indicated that it was not a wild type, suggesting that it contained KRAS mutation...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27591291/detection-of-kras-mutations-in-circulating-tumor-dna-by-digital-pcr-in-early-stages-of-pancreatic-cancer
#6
Nora Brychta, Thomas Krahn, Oliver von Ahsen
BACKGROUND: Since surgical removal remains the only cure for pancreatic cancer, early detection is of utmost importance. Circulating biomarkers have potential as diagnostic tool for pancreatic cancer, which typically causes clinical symptoms only in advanced stage. Because of their high prevalence in pancreatic cancer, KRAS proto-oncogene, GTPase [KRAS (previous name: Kirsten rat sarcoma viral oncogene homolog)] mutations may be used to identify tumor-derived circulating plasma DNA. Here we tested the diagnostic sensitivity of chip based digital PCR for the detection of KRAS mutations in circulating tumor DNA (ctDNA) in early stage pancreatic cancer...
September 2, 2016: Clinical Chemistry
https://www.readbyqxmd.com/read/27506872/recent-advances-in-cancer-drug-discovery-targeting-ras
#7
Candice Y Wilson, Peter Tolias
Mutated RAS is present in 30% of human tumors, appearing in 90% of pancreatic, 45% of colon and 35% of lung cancers. These high occurrences make RAS one of the most important drug targets in oncology. Three decades of effort to target RAS have been unsuccessful in generating drug therapies suggesting that it might represent an 'undruggable' target. However, recent reports highlighting new approaches for targeting RAS have uncovered more information on protein structure and identified new binding pockets. Efforts to target the KRAS G12C mutation specifically have shown promising results whereas other approaches have targeted various protein complexes...
August 6, 2016: Drug Discovery Today
https://www.readbyqxmd.com/read/27463838/defeat-mutant-kras-with-synthetic-lethality
#8
Xiufeng Pang, Mingyao Liu
Ras proteins are considered as the founding members of a large superfamily of small GTPases that control fundamental cellular functions. Mutationally activated RAS genes were discovered in human cancer cells more than 3 decades ago, but intensive efforts on Ras structure, biochemistry, function and signaling continue even now. Because mutant Ras proteins are inherently difficult to inhibit and have yet been therapeutically conquered, it was designated as "the Everest of oncogenes" in the cancer genome landscape, further promoting a "renaissance" in RAS research...
July 27, 2016: Small GTPases
https://www.readbyqxmd.com/read/27358379/outcome-according-to-kras-nras-and-braf-mutation-as-well-as-kras-mutation-variants-pooled-analysis-of-five-randomized-trials-in-metastatic-colorectal-cancer-by-the-aio-colorectal-cancer-study-group
#9
D P Modest, I Ricard, V Heinemann, S Hegewisch-Becker, W Schmiegel, R Porschen, S Stintzing, U Graeven, D Arnold, L F von Weikersthal, C Giessen-Jung, A Stahler, H J Schmoll, A Jung, T Kirchner, A Tannapfel, A Reinacher-Schick
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models. RESULTS: In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation...
September 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27336603/specific-kras-amino-acid-substitutions-and-egfr-mutations-predict-site-specific-recurrence-and-metastasis-following-non-small-cell-lung-cancer-surgery
#10
Stéphane Renaud, Joseph Seitlinger, Pierre-Emmanuel Falcoz, Mickaël Schaeffer, Anne-Claire Voegeli, Michèle Legrain, Michèle Beau-Faller, Gilbert Massard
BACKGROUND: We aimed to evaluate whether EGFR mutations (mEGFR) and KRAS amino acid substitutions can predict first site of recurrence or metastasis after non-small-cell lung cancer (NSCLC) surgery. METHODS: Data were reviewed from 481 patients who underwent thoracic surgery for NSCLC between 2007 and 2012. RESULTS: Patients with KRAS G12C developed significantly more bone metastases compared with the remainder of the cohort (59% vs 16%, P<0...
July 26, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27329432/comparative-metabolomics-profiling-of-isogenic-kras-wild-type-and-mutant-nsclc-cells-in-vitro-and-in-vivo
#11
Laura Brunelli, Elisa Caiola, Mirko Marabese, Massimo Broggini, Roberta Pastorelli
Oncogenes induce metabolic reprogramming on cancer cells. Recently, G12C KRAS mutation in isogenic NSCLC cell line has been shown to be a key player in promoting metabolic rewiring mainly through the regulation of glutamine metabolism to fuel growth and proliferation. Even though cell lines possessing many of the genetic backgrounds of the primary cancer they derive from could be a valuable pre-clinical model, they do not have the additional complexity present in the whole tumor that impact metabolism. This preliminary study is aimed to explore how cancer cell metabolism in culture might recapitulate the metabolic alterations present in vivo...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27312529/molecular-landscape-of-acquired-resistance-to-targeted-therapy-combinations-in-braf-mutant-colorectal-cancer
#12
Daniele Oddo, Erin M Sennott, Ludovic Barault, Emanuele Valtorta, Sabrina Arena, Andrea Cassingena, Genny Filiciotto, Giulia Marzolla, Elena Elez, Robin M J M van Geel, Alice Bartolini, Giovanni Crisafulli, Valentina Boscaro, Jason T Godfrey, Michela Buscarino, Carlotta Cancelliere, Michael Linnebacher, Giorgio Corti, Mauro Truini, Giulia Siravegna, Julieta Grasselli, Margherita Gallicchio, René Bernards, Jan H M Schellens, Josep Tabernero, Jeffrey A Engelman, Andrea Sartore-Bianchi, Alberto Bardelli, Salvatore Siena, Ryan B Corcoran, Federica Di Nicolantonio
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation. We generated a broad panel of BRAF-mutant resistant cell line models across seven different clinically relevant drug combinations. Combinatorial drug treatments were able to abrogate ERK1/2 phosphorylation in parental-sensitive cells, but not in their resistant counterparts, indicating that resistant cells escaped drug treatments through one or more mechanisms leading to biochemical reactivation of the MAPK signaling pathway...
August 1, 2016: Cancer Research
https://www.readbyqxmd.com/read/27304188/heterogeneity-of-resistance-mutations-detectable-by-next-generation-sequencing-in-tki-treated-lung-adenocarcinoma
#13
Deborah A Belchis, Li-Hui Tseng, Thomas Gniadek, Lisa Haley, Parvez Lokhandwala, Peter Illei, Christopher D Gocke, Patrick Forde, Julie Brahmer, Frederic B Askin, James R Eshleman, Ming-Tseh Lin
EGFR-mutated lung adenocarcinomas routinely develop resistance to tyrosine kinase inhibitors (TKI). To better characterize the relative frequencies of the resistance mechanisms, we analyzed 48 EGFR-mutated TKI-resistant specimens from 41 patients. Next generation sequencing of post-treatment specimens detected EGFR p.T790M in 31 (79%) of 39 patients, PIK3CA mutations in 10 (26%), EGFR p.S768_V769delinsIL in one, and KRAS p.G12C in one. Five PIK3CA mutations were outside of codons 542, 545, and 1047. Three of four pre-treatment specimens did not carry the PIK3CA mutation found in the post-treatment sample...
June 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/27283493/different-metabolic-responses-to-pi3k-inhibition-in-nsclc-cells-harboring-wild-type-and-g12c-mutant-kras
#14
Elisa Caiola, Laura Brunelli, Mirko Marabese, Massimo Broggini, Monica Lupi, Roberta Pastorelli
KRAS mutations in non-small-cell lung cancer (NSCLC) patients are considered a negative predictive factor and indicate poor response to anticancer treatments. KRAS mutations lead to activation of the PI3K/akt/mTOR pathway, whose inhibition remains a challenging clinical target. Since the PI3K/akt/mTOR pathway and KRAS oncogene mutations all have roles in cancer cell metabolism, we investigated whether the activity of PI3K/akt/mTOR inhibitors (BEZ235 and BKM120) in cells harboring different KRAS status is related to their metabolic effect...
June 6, 2016: Oncotarget
https://www.readbyqxmd.com/read/27267833/genomic-alterations-in-biliary-tract-cancer-using-targeted-sequencing
#15
Kwai Han Yoo, Nayoung K D Kim, Woo Il Kwon, Chung Lee, Sun Young Kim, Jiryeon Jang, Jungmi Ahn, Mihyun Kang, Hyojin Jang, Seung Tae Kim, Soomin Ahn, Kee-Taek Jang, Young Suk Park, Woong-Yang Park, Jeeyun Lee, Jin Seok Heo, Joon Oh Park
BACKGROUND: Biliary tract cancers (BTCs) are rare and heterogeneous group of tumors classified anatomically into intrahepatic and extrahepatic bile ducts and gallbladder adenocarcinomas. Patient-derived tumor cell (PDC) models with genome analysis can be a valuable platform to develop a method to overcome the clinical barrier on BTCs. MATERIAL AND METHODS: Between January 2012 and June 2015, 40 BTC patients' samples were collected. PDCs were isolated and cultured from surgical specimens, biopsy tissues, or malignant effusions including ascites and pleural fluid...
June 2016: Translational Oncology
https://www.readbyqxmd.com/read/27195433/utilization-of-cell-transfer-technique-for-molecular-testing-on-hematoxylin-eosin-stained-sections
#16
Howard H Wu, Stephen M Jovonovich, Melissa Randolph, Kristin M Post, Joyashree D Sen, Kendra Curless, Liang Cheng
Context .- In some instances the standard method of doing molecular testing from formalin-fixed, paraffin-embedded block is not possible because of limited tissue. Tumor cell-enriched cell-transfer technique has been proven useful for performing immunocytochemistry and molecular testing on cytologic smears. Objective .- To establish the cell-transfer technique as a viable option for isolating tumor cells from hematoxylin-eosin (H&E)-stained slides. Design .- Molecular testing was performed by using the cell-transfer technique on 97 archived H&E-stained slides from a variety of different tumors...
May 19, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27068338/the-potential-utility-of-re-mining-results-of-somatic-mutation-testing-kras-status-in-lung-adenocarcinoma
#17
Anna Biernacka, Peter D Tsongalis, Jason D Peterson, Francine B de Abreu, Candice C Black, Edward J Gutmann, Xiaoying Liu, Laura J Tafe, Christopher I Amos, Gregory J Tsongalis
KRAS mutant non-small cell lung cancers (NSCLCs) vary in clinical outcome depending on which specific KRAS mutation is present. Shorter progression free survival has been associated with KRAS variants G12C and G12V. Cell lines with these variants depend to a greater extent on the RAS/RAF/MEK/ERK signaling pathway and become more susceptible to MEK inhibition. Because different KRAS mutations may lead to altered drug sensitivity, we aimed to determine specific KRAS mutation status in a NSCLC patient cohort at our institution...
May 2016: Cancer Genetics
https://www.readbyqxmd.com/read/26992209/clinicopathologic-characteristics-of-egfr-kras-and-alk-alterations-in-6-595-lung-cancers
#18
Boram Lee, Taebum Lee, Se-Hoon Lee, Yoon La Choi, Joungho Han
BACKGROUND: EGFR, KRAS, and ALK alterations are major genetic changes found in non-small cell lung cancers (NSCLCs). Testing advanced lung adenocarcinoma tumors for these three genes is now standard care. The purpose of this study was to investigate the clinicopathologic expression pattern of these three genes in East Asian NSCLC patients. PATIENTS AND METHODS: We conducted a retrospective study of all patients tested for mutations of these three genes at a single institute in Korea between 2006 and 2014...
April 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/26977877/selective-targeting-of-the-kras-g12c-mutant-kicking-kras-when-it-s-down
#19
REVIEW
G Aaron Hobbs, Alfred Wittinghofer, Channing J Der
Two recent studies evaluated a small molecule that specifically binds to and inactivates the KRAS G12C mutant. The new findings argue that the perception that mutant KRAS is persistently frozen in its active GTP-bound form may not be accurate.
March 14, 2016: Cancer Cell
https://www.readbyqxmd.com/read/26977001/the-prognostic-role-of-kras-mutation-in-patients-with-advanced-nsclc-treated-with-second-or-third-line-chemotherapy
#20
Martin Svaton, Ondrej Fiala, Milos Pesek, Zbynek Bortlicek, Marek Minarik, Lucie Benesova, Ondrej Topolcan
BACKGROUND/AIM: The prognostic and predictive value of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. The present study aimed at the elucidation of the role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second- or third-line chemotherapy. PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed...
March 2016: Anticancer Research
keyword
keyword
63068
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"